Discover why Altimmune (ALT) and Viking Therapeutics (VKTX) are top picks for high-risk investors. Click here to read my most ...

"I am also pleased to report that the cash runway now extends into 2028 with the re-allocation of resources to our therapeutics pipeline." Recent Corporate Highlights Arcturus is advancing ...

The strategic partnership is likely to diversify CRISPR Therapeutics’ pipeline by adding Sirius’s lead candidate, SRSD107, a next-generation, long-acting siRNA therapy, which is being ...

What potential does the company’s pipeline hold for addressing unmet medical needs? Contineum Therapeutics’ pipeline holds significant potential for addressing unmet medical needs across ...

It also covers the Hunter Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this ...

What potential does the company’s pipeline hold for addressing unmet medical needs? Contineum Therapeutics’ pipeline holds significant potential for addressing unmet medical needs across several ...

“I am also pleased to report that the cash runway now extends into 2028 with the re-allocation of resources to our therapeutics pipeline.” The Company recently completed the recruitment of 212 ...

Fate Therapeutics FATE reported a loss of 32 cents ... Its immuno-oncology pipeline includes iPSC-derived natural killer (NK) cells and T-cell product candidates. A phase I study of FT819, a ...